Bilimsel çalışmalar

Uzm. Dr. Mert Kaşkal

42 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön
  1. Cytotoxic effect of famotidine in breast adenocarcinoma cells line

    Northern Clinics of Istanbul, 2026

    DOI 10.14744/nci.2026.55899 PMID 41940059 Açık erişimli tam metinKaynak: OpenAlex

  2. Cross-exclusion of patients with chronic obstructive pulmonary disease and heart failure in randomized controlled drug trials

    Respiratory Medicine, 2026

    DOI 10.1016/j.rmed.2026.108781 PMID 41862104 Kaynak: ORCID

  3. Albumin levels and risk of early cardiovascular complications after endovascular thrombectomy for acute ischaemic stroke

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-50280-0 PMID 42032112 Açık erişimli tam metinKaynak: ORCID

  4. Long-term prognosis in Takotsubo syndrome compared to heart failure: observations from a global federated research network

    ESC Heart Failure, 2026

    DOI 10.1093/eschf/xvag065 PMID 41761829 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  5. Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network

    BMC Pulmonary Medicine, 2026

    DOI 10.1186/s12890-026-04216-z PMID 41782097 Açık erişimli tam metinKaynak: ORCID

  6. Prognostic Impact of New-Onset Atrial Fibrillation After Cardiac Arrest: Observations From a Federated Research Network

    Journal of Cardiovascular Electrophysiology, 2026

    DOI 10.1111/jce.70288 PMID 41668553 Açık erişimli tam metinKaynak: ORCID

  7. Additional file 2 of Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network

    Figshare, 2026

    DOI 10.6084/m9.figshare.31985912 Açık erişimli tam metinKaynak: OpenAlex

  8. Additional file 1 of Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network

    Figshare, 2026

    DOI 10.6084/m9.figshare.31985909 Açık erişimli tam metinKaynak: OpenAlex

  9. Additional file 6 of Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network

    Figshare, 2026

    DOI 10.6084/m9.figshare.31985924 Açık erişimli tam metinKaynak: OpenAlex

  10. Additional file 7 of Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network

    Figshare, 2026

    DOI 10.6084/m9.figshare.31985927 Açık erişimli tam metinKaynak: OpenAlex

  11. Additional file 4 of Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network

    Figshare, 2026

    DOI 10.6084/m9.figshare.31985918 Açık erişimli tam metinKaynak: OpenAlex

  12. Additional file 5 of Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network

    Figshare, 2026

    DOI 10.6084/m9.figshare.31985921.v1 Açık erişimli tam metinKaynak: OpenAlex

  13. Additional file 8 of Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network

    Figshare, 2026

    DOI 10.6084/m9.figshare.31985930.v1 Açık erişimli tam metinKaynak: OpenAlex

  14. Additional file 3 of Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network

    Figshare, 2026

    DOI 10.6084/m9.figshare.31985915 Açık erişimli tam metinKaynak: OpenAlex

  15. The use of glucagon-like peptide-1 agonists as a treatment for obesity in older people: risks and benefits

    Current Opinion in Clinical Nutrition & Metabolic Care, 2026

    DOI 10.1097/mco.0000000000001262 PMID 42935438 Kaynak: OpenAlex

  16. Frailty and Poor Sleep Patterns

    JACC: Asia, 2025

    DOI 10.1016/j.jacasi.2025.09.004 PMID 41198377 Açık erişimli tam metinKaynak: ORCID

  17. The clinical impact of chronopharmacology on current medicine

    Naunyn-Schmiedeberg's Archives of Pharmacology, 2025

    DOI 10.1007/s00210-025-03788-7 PMID 39792169 11 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  18. The risk of acute exacerbations of chronic obstructive pulmonary disease following acute myocardial infarction

    European Respiratory Journal, 2025

    DOI 10.1183/13993003.congress-2025.pa3477 Kaynak: OpenAlex

  19. Risk of adverse events in takotsubo syndrome compared to heart failure: observations from a global federated network

    European Heart Journal, 2025

    DOI 10.1093/eurheartj/ehaf784.1082 Kaynak: OpenAlex

  20. Use of lipid-lowering drugs in restricted health access settings: Results from the Trends in Drug Utilization During COVID-19 Pandemic in Turkey (PANDUTI-TR) study

    Vascular Pharmacology, 2024

    DOI 10.1016/j.vph.2024.107382 PMID 38815702 6 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  21. Assessing effects of tamoxifen on tolerance, dependence, and glutamate and glutamine levels in frontal cortex and hippocampus in chronic morphine treatment

    Behavioural Brain Research, 2024

    DOI 10.1016/j.bbr.2024.114897 PMID 38331101 1 atıf (Europe PMC) Kaynak: ORCID

  22. Evaluation of the teratogenic effects of pregabalin usage during pregnancy: A multicenter case-control study

    Northern Clinics of Istanbul, 2024

    DOI 10.14744/nci.2024.57702 PMID 39431036 Açık erişimli tam metinKaynak: ORCID

  23. Comparison of primary care prescriptions for old and very old hypertensive patients

    TURKISH JOURNAL OF MEDICAL SCIENCES, 2023

    DOI 10.55730/1300-0144.5618 PMID 37476867 3 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  24. Favipiravir Does Not Appear to Be a Major Teratogen: Case Series from Türkiye

    Journal of Gynecology Obstetrics and Human Reproduction, 2023

    DOI 10.1016/j.jogoh.2023.102693 PMID 37984519 4 atıf (OpenAlex) Açık erişimli tam metinKaynak: ORCID

  25. Favipiravir Does Not Appear to Be a Major Teratogen: Case Series from Türkiye

    Ssrn, 2023

    DOI 10.2139/ssrn.4443306 Açık erişimli tam metinKaynak: Europe PMC

  26. Evaluation of Stress Response in Middle-Aged Male Diabetic Hypertensive Patients

    Journal of Clinical Endocrinology and Metabolism, 2023

    DOI 10.1210/clinem/dgad122 PMID 36880261 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  27. Iohexol exposure in the first trimester of the pregnancy, a case report

    Neurotoxicology and Teratology, 2023

    DOI 10.1016/j.ntt.2023.107229 1 atıf (OpenAlex) Kaynak: OpenAlex

  28. The evaluation of drug adherence in primary health care : A single center epidemiological study

    Dspace Repository (Marmara Üniversitesi), 2023

    Kaynak: OpenAlex

  29. Gebeliğin ilk trimestırında iohexol maruziyeti, vaka sunumu

    Dspace Repository (Marmara Üniversitesi), 2023

    Kaynak: OpenAlex

  30. Efficacy of topical dexamethasone eye drops in preventing ocular inflammation and cystoid macular edema following uncomplicated cataract surgery with or without injection of a single dose perioperative subtenon triamcinolone acetonide

    Cutaneous and Ocular Toxicology, 2022

    DOI 10.1080/15569527.2022.2136193 PMID 36308286 5 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  31. Long term results of three anti-vascular endothelial growth factor agents in pachychoroid neovasculopathy

    Cutaneous and Ocular Toxicology, 2022

    DOI 10.1080/15569527.2022.2068150 PMID 35579866 5 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  32. Brief communication: A case of cyclophosphamide exposure in the first trimester of pregnancy

    European Journal of Obstetrics and Gynecology and Reproductive Biology, 2022

    DOI 10.1016/j.ejogrb.2022.03.029 PMID 35341650 Açık erişimli tam metinKaynak: ORCID

  33. THE INFLUENCE OF PHARMACOGENETICS IN THE CLINICAL USE OF ANTIDEPRESSANTS

    Kocatepe Tıp Dergisi, 2022

    DOI 10.18229/kocatepetip.892349 Açık erişimli tam metinKaynak: ORCID

  34. Evaluation of Risk Factors Associated With Antihypertensive Treatment Success Employing Data Mining Techniques

    Journal of Cardiovascular Pharmacology and Therapeutics, 2022

    DOI 10.1177/10742484221136758 PMID 36324213 Açık erişimli tam metinKaynak: ORCID

  35. Renal pathologies and mesalazine use in pregnancy

    Neurotoxicology and Teratology, 2022

    Kaynak: ORCID

  36. Gebelikte mesalazin kullanımı ve renal patolojiler

    Dspace Repository (Marmara Üniversitesi), 2022

    Açık erişimli tam metinKaynak: OpenAlex

  37. Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial

    Pharmaceutics, 2021

    DOI 10.3390/pharmaceutics13111768 PMID 34834183 15 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  38. "Evaluation of the Effect of a Mobile Phone Application on Treatment Success and Drug Adherence in Hypertensive Patients"

    Biomedical Journal of Scientific & Technical Research, 2021

    DOI 10.26717/bjstr.2021.39.006373 Açık erişimli tam metinKaynak: ORCID

  39. A case of pancreatic enzyme elevation due to use of statins

    DergiPark (Istanbul University), 2021

    Açık erişimli tam metinKaynak: OpenAlex

  40. Chrono-pharmacological effects of antihypertensive drugs

    European Heart Journal, 2020

    DOI 10.1093/eurheartj/ehaa213 PMID 32298408 5 atıf (Europe PMC) Kaynak: ORCID

  41. Hypersensitivity reaction induced with renin-angiotensin-aldosterone system blocker antihypertensive agents

    Demiroglu Science University Florence Nightingale Journal of Medicine, 2020

    DOI 10.5606/fng.btd.2020.25013 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: ORCID

  42. Percutaneous cholecystostomy: A curative treatment modality forelderly & high asa score acute cholecystitis patients,Perkütan kolesistostomi: Yaşlı ve yüksek ASA skorlu akut kolesistitli hastalarda küratif tedavi yöntemi

    Ulusal Travma Ve Acil Cerrahi Dergisi, 2017

    DOI 10.5505/tjtes.2016.26053 PMID 28261768 7 atıf (Europe PMC) Kaynak: ORCID